Market Cap 717.24M
Revenue (ttm) 0.00
Net Income (ttm) -3.35M
EPS (ttm) N/A
PE Ratio 3.98
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -2.16
Volume 1,944,900
Avg Vol 1,883,684
Day's Range N/A - N/A
Shares Out 72.38M
Stochastic %K 62%
Beta 2.52
Analysts Strong Sell
Price Target $44.00

Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has...

Industry: Biotechnology
Sector: Healthcare
Phone: 206 676 5000
Address:
The Omeros Building, 201 Elliott Avenue West, Seattle, United States
Arad288
Arad288 Jul. 1 at 3:18 PM
1 · Reply
SteadyasSheGoes
SteadyasSheGoes Jul. 1 at 3:07 PM
$OMER J1289 PR dated 4/16; – Permanent, product-specific J-code facilitates efficient claims and reimbursement – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026.
1 · Reply
LeaLeb
LeaLeb Jul. 1 at 2:25 PM
$OMER I guess not material, maybe it's in the "soon", "near term", or departing executives catagory in Greg's playbook.
0 · Reply
gogosingkorean
gogosingkorean Jul. 1 at 1:47 PM
$OMER The fact that Omeros will ultimately end in a buyout remains unchanged, though the process is incredibly grueling. Fortunately, I was able to sell my entire position upon the news of the EMA cancellation and bought back in, which increased my share count by 20%. It seems there are no significant catalysts until the debt is addressed.
0 · Reply
resq1
resq1 Jul. 1 at 12:16 PM
$OMER it's material. But we are also reading below FDA approval values. I would say FDA approval is rather material, no?
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Jul. 1 at 11:54 AM
$OMER I dont think j code is material
4 · Reply
TRYII
TRYII Jul. 1 at 11:50 AM
$OMER J-code is "Material"
0 · Reply
StatsGuru
StatsGuru Jul. 1 at 9:09 AM
$OMER J-code = revenue multiplier
0 · Reply
Biotechinvestor101
Biotechinvestor101 Jul. 1 at 7:33 AM
$OMER first J code day, many to follow😊💰
0 · Reply
naturegirl669
naturegirl669 Jul. 1 at 4:10 AM
$OMER - Most Realistic Off‑Label Expansion: Post‑transplant complications Complement‑mediated kidney diseases Catastrophic hematologic TMAs ARDS Long COVID Multi‑organ failure Neurologic complement vasculopathies
1 · Reply
Latest News on OMER
Omeros stock crashes on regulatory setback: buy the dip?

Jun 26, 2026, 2:11 PM EDT - 4 days ago

Omeros stock crashes on regulatory setback: buy the dip?


Omeros Transcript: AGM 2026

Jun 18, 2026, 1:00 PM EDT - 12 days ago

Omeros Transcript: AGM 2026


Omeros trading resumes

2026-06-12T13:45:42.000Z - 19 days ago

Omeros trading resumes


Omeros trading halted, volatility trading pause

2026-06-12T13:35:42.000Z - 19 days ago

Omeros trading halted, volatility trading pause


Omeros Earnings Call Transcript: Q1 2026

May 13, 2026, 4:30 PM EDT - 6 weeks ago

Omeros Earnings Call Transcript: Q1 2026


Omeros Earnings release: Q1 2026

May 13, 2026, 4:30 PM EDT - 6 weeks ago

Omeros Earnings release: Q1 2026


Omeros Quarterly report: Q1 2026

May 13, 2026, 4:30 PM EDT - 6 weeks ago

Omeros Quarterly report: Q1 2026


Omeros reports Q1 adjusted EPS (24c), consensus (28c)

2026-05-13T20:27:08.000Z - 6 weeks ago

Omeros reports Q1 adjusted EPS (24c), consensus (28c)


Omeros Corporation Reports First Quarter 2026 Financial Results

May 13, 2026, 4:02 PM EDT - 6 weeks ago

Omeros Corporation Reports First Quarter 2026 Financial Results


Omeros Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Omeros Proxy statement: Proxy filing


Omeros Earnings Call Transcript: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings Call Transcript: Q4 2025


Omeros Earnings release: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Earnings release: Q4 2025


Omeros Annual report: Q4 2025

Mar 31, 2026, 4:30 PM EDT - 3 months ago

Omeros Annual report: Q4 2025


Omeros reports Q4 EPS $1.22, consensus 36c

2026-03-31T20:05:48.000Z - 3 months ago

Omeros reports Q4 EPS $1.22, consensus 36c


Omeros announces first commercial sales of Yartemlea

2026-01-27T14:20:24.000Z - 5 months ago

Omeros announces first commercial sales of Yartemlea


Omeros Announces First Commercial Sales of YARTEMLEA®

Jan 27, 2026, 9:00 AM EST - 5 months ago

Omeros Announces First Commercial Sales of YARTEMLEA®


Omeros price target raised to $40 from $20 at H.C. Wainwright

2026-01-08T11:11:35.000Z - 6 months ago

Omeros price target raised to $40 from $20 at H.C. Wainwright


Omeros prices transplant complication drug at $36,000 per dose

Jan 7, 2026, 6:50 PM EST - 6 months ago

Omeros prices transplant complication drug at $36,000 per dose


Omeros Transcript: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 6 months ago

Omeros Transcript: FDA Announcement


Omeros Press release: FDA Announcement

Jan 7, 2026, 4:30 PM EST - 6 months ago

Omeros Press release: FDA Announcement


Omeros trading resumes

2025-12-24T15:15:15.000Z - 6 months ago

Omeros trading resumes


Omeros trading halted, volatility trading pause

2025-12-24T15:10:19.000Z - 6 months ago

Omeros trading halted, volatility trading pause


Omeros Earnings Call Transcript: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Earnings Call Transcript: Q3 2025


Omeros Quarterly report: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Quarterly report: Q3 2025


Omeros Earnings release: Q3 2025

Nov 13, 2025, 4:30 PM EST - 8 months ago

Omeros Earnings release: Q3 2025


Omeros Corporation Reports Third Quarter 2025 Financial Results

Nov 13, 2025, 4:11 PM EST - 8 months ago

Omeros Corporation Reports Third Quarter 2025 Financial Results


Omeros Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Omeros Earnings Call Transcript: Q2 2025


Omeros Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Omeros Quarterly report: Q2 2025


Omeros Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 11 months ago

Omeros Earnings release: Q2 2025


Omeros Corporation Reports Second Quarter 2025 Financial Results

Aug 14, 2025, 4:02 PM EDT - 11 months ago

Omeros Corporation Reports Second Quarter 2025 Financial Results


Omeros Proxy statement: Proxy Filing

May 30, 2025, 8:00 AM EDT - 1 year ago

Omeros Proxy statement: Proxy Filing


Omeros Earnings Call Transcript: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q1 2025


Omeros Quarterly report: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Quarterly report: Q1 2025


Omeros Earnings release: Q1 2025

May 15, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q1 2025


Omeros Earnings Call Transcript: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings Call Transcript: Q4 2024


Omeros Annual report: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Annual report: Q4 2024


Omeros Earnings release: Q4 2024

Mar 31, 2025, 4:30 PM EDT - 1 year ago

Omeros Earnings release: Q4 2024


Omeros Earnings Call Transcript: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings Call Transcript: Q3 2024


Omeros Earnings release: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Earnings release: Q3 2024


Omeros Quarterly report: Q3 2024

Nov 13, 2024, 4:30 PM EST - 1 year ago

Omeros Quarterly report: Q3 2024


Omeros Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings Call Transcript: Q2 2024


Omeros Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Omeros Quarterly report: Q2 2024


Omeros Earnings release: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 2 years ago

Omeros Earnings release: Q2 2024


Arad288
Arad288 Jul. 1 at 3:18 PM
1 · Reply
SteadyasSheGoes
SteadyasSheGoes Jul. 1 at 3:07 PM
$OMER J1289 PR dated 4/16; – Permanent, product-specific J-code facilitates efficient claims and reimbursement – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026.
1 · Reply
LeaLeb
LeaLeb Jul. 1 at 2:25 PM
$OMER I guess not material, maybe it's in the "soon", "near term", or departing executives catagory in Greg's playbook.
0 · Reply
gogosingkorean
gogosingkorean Jul. 1 at 1:47 PM
$OMER The fact that Omeros will ultimately end in a buyout remains unchanged, though the process is incredibly grueling. Fortunately, I was able to sell my entire position upon the news of the EMA cancellation and bought back in, which increased my share count by 20%. It seems there are no significant catalysts until the debt is addressed.
0 · Reply
resq1
resq1 Jul. 1 at 12:16 PM
$OMER it's material. But we are also reading below FDA approval values. I would say FDA approval is rather material, no?
0 · Reply
UltimoDaBaggie
UltimoDaBaggie Jul. 1 at 11:54 AM
$OMER I dont think j code is material
4 · Reply
TRYII
TRYII Jul. 1 at 11:50 AM
$OMER J-code is "Material"
0 · Reply
StatsGuru
StatsGuru Jul. 1 at 9:09 AM
$OMER J-code = revenue multiplier
0 · Reply
Biotechinvestor101
Biotechinvestor101 Jul. 1 at 7:33 AM
$OMER first J code day, many to follow😊💰
0 · Reply
naturegirl669
naturegirl669 Jul. 1 at 4:10 AM
$OMER - Most Realistic Off‑Label Expansion: Post‑transplant complications Complement‑mediated kidney diseases Catastrophic hematologic TMAs ARDS Long COVID Multi‑organ failure Neurologic complement vasculopathies
1 · Reply
BigWayner
BigWayner Jul. 1 at 1:23 AM
$OMER Give me a J. “J”! Give me a C. “C”! Give me an “ode”. “ode”! What does it spell? J-Code!!!
3 · Reply
Tyler1100
Tyler1100 Jul. 1 at 1:06 AM
$OMER from your keyboard to Gods ears
0 · Reply
haxhiua1
haxhiua1 Jun. 30 at 9:36 PM
$OMER when omeros announced buying of the convertibles, i was sure major cashflow is coming in. But then Greg wa asked in ASM and he just noted that its basic debt managment an they believe they can re-finance it later if cash needed. He was also asked if Yart is following positive growth trajectory to which he seemed uncomfortable, although he did say yes. Super annoying 😩 Anyways, each quarter will now include a sales catalyst, and what excites me as well is selection of oms1029 indication and starting phase 2. If a good one, it can easily pump the shares by a few dollars. Finally, Im not sure how Q2 sales will turn out, but what really matters is the period after the J-code and, hopefully, NTAP. In Q2 review, If July and August sales are strong, Greg could smoke the shorts by stating that first-half Q3 sales are exceeding expectations and accelerating the growth trajectory. Knowing Greg, though, he’ll probably just keep it to himself and not give an F about keeping us up to date.
0 · Reply
MayorofMNKD
MayorofMNKD Jun. 30 at 8:00 PM
$OMER ….looks like j code pr tomorrow
3 · Reply
in_GOD_alone
in_GOD_alone Jun. 30 at 7:57 PM
$OMER I sold some cover calls. Thank you to whoever bought them.
1 · Reply
StatsGuru
StatsGuru Jun. 30 at 6:17 PM
$OMER Greg - spend some money on the PR tomorrow!
2 · Reply
hmb
hmb Jun. 30 at 4:54 PM
$OMER at support. Weekly and monthly Charts look primed for a launch to ~$20+. Catalysts brewing(lots of stuff I don’t understand or care to) UNDERVALUED BY 4-10x. Price targets of 2-4x. Sales likely increasing. J code. Buy backs signed deals with a top 5 company on earth. I really need more shares
1 · Reply
Arad288
Arad288 Jun. 30 at 4:09 PM
$OMER let me chime in here on the revenue . Greg said that the whole company will be cash neutral or positive by mid 2027 ,right ? At the time there was no European approval and most people say that even with the EMA we would not see any money from Europe for 18 months or so which would be way past mid 2027. I don’t think he can predict revenue from Europe before approval. Was Greg lying 🤥 to us on the revenue or he o owe what the numbers are that we do not ? Go ahead and let me know what you think about it .
1 · Reply
Ajeannet
Ajeannet Jun. 30 at 4:08 PM
$OMER Run up ???? Did you mean down?
1 · Reply
JFais
JFais Jun. 30 at 3:24 PM
Coffee at the Close replay $XBI https://youtu.be/IkukIiodfsU?si=gXmXi96Oo9KezLLa A few topics covered: -How we respond to biotech "gut punches" / negative news (choose logic over emotion) $OMER -Regulatory reversals & impact on sentiment $QURE -How @JoseRestonVA views selling pressure (examples with $APGE and $BHVN 1.0) -Our💡moment (less is more vs overtrading) -Importance of waiting for the right pitches vs chasing at highs
1 · Reply
111ggg
111ggg Jun. 30 at 1:50 PM
$OMER look for some consolidation over next few days. That was a big runup the past few days.
3 · Reply
resq1
resq1 Jun. 30 at 1:43 PM
$OMER no brainer at this steep discount. Looking for 2bn mkt cap- minimum by end of this year when results come through
2 · Reply